Middle east blood plasma derivative Market Expected to Reach $3,037.0 million by 2032 | CAGR of 9.4%

According to a new report published by Allied Market Research, titled, “Middle east blood plasma derivative Market by type, application and end User: Opportunity Analysis and Industry Forecast, 2022–2032", the middle East blood plasma derivative market size was valued at $ 1,115.1 million in 2021, and is projected to reach $ 3,037.0 million by 2032, registering a CAGR of 9.4% from 2022 to 2032. 

Red blood cells, white blood cells, and platelets are suspended in the clear liquid blood component known as blood plasma. It is essential for sustaining the right pH balance in the body and moving nutrients across the body.

Albumin, fibrinogen, immunoglobulins, protease inhibitors, and coagulation factors are just a few of the more than 100 distinct proteins that make it up. Plasma derivatives are goods made from blood plasma after fractionation and are frequently used to treat a wide range of illnesses. Albumin, factor VIII and IX, anti-inhibitor coagulation complex (AICC), immunoglobulins, such as Rh immune globulin, alpha 1-proteinase inhibitor concentrate, and anti-thrombin III concentrate are some of these products. 

Factors that drive the growth of the Middle East blood plasma derivative market include rise in the number of key players that manufacture products for blood plasma derivatives, increase in the research activities for plasma derivatives and wide range of applications of plasma derivatives. 

For instance, plasma derivatives therapy is used in the treatment of different immunodeficiency disorders, infectious disorders, and bleeding disorders. Thus, rise in application of plasma derivatives for treatment purpose is anticipated to drive the growth of plasma derivatives market. Moreover, rise in research activities regarding convalescent plasma by different countries is attributes to drive the growth of market. 

Moreover, rise in the usage of plasma derivatives to treat hemophilia is anticipated to drive the growth of the East blood plasma derivative market. For instance, according to the survey conducted by World Federation ofHemophilia, in 2020, in Saudi Arabia, 1,067 people were suffering from hemophilia. As per the same source, Saudi Arabia used 148,120,00 units Factor IIV for the treatment of hemophilia in 2020. In addition, rise in geriatric population drives the plasma derivative market growth. As geriatric population is more susceptible to different infectious diseases, bleeding diseases and immunodeficiency diseases, it drives the demand for blood plasma derivatives for treatment purposes. Thus, increase in number of geriatric populations drives the need of plasma derivatives and boosts the market growth. 

By type, the market is segmented into Albumin, Factor VII, Factor IX concentrate, anti-coagulation factor, Rh-immunoglobulin, and others. The others segment dominated the market in 2021 and is expected to continue this trend during the forecast period, owing to effectiveness of alpha 1 protease as blood plasma derivative for treatment of immunodeficiency diseases, infectious diseases, and viral diseases. 

By application, the market is segmented into immunodeficiency diseases, bleeding disorders, liver conditions, and others. The bleeding disorders segment dominated the market in 2021 and is expected to continue this trend during the forecast period, owing to rise in application of blood plasma derivatives for treatment of hemophilia and increase in prevalence of hemophilia. 

By end user, the market is divided into hospitals, clinics, and transfusion centers. The hospitals segment dominated the market in 2021 and is expected to continue this trend during the forecast period, owing to rise in number of hospitals and increase in expenditure by hospitals for development of healthcare sector.

Key Findings Of Study 

• By type, the others the segment was the highest contributor to the market in 2021.
• By application, the bleeding disorders the segment was the highest contributor to the East blood plasma derivative market in 2021.
• By end user, the hospitals segment dominated the East blood plasma derivative market in 2021, and is expected to continue this trend during the forecast period.